title: [Influence of a W3 fatty acids oral enhanced formula in clinical and biochemical parameters of head and neck cancer ambulatory patients].
abstract: BACKGROUND
  Postsurgical patients with head and neck cancer could have a high rate of ambulatory complications. The aim of our study was to investigate whether oral ambulatory nutrition of post surgical head and neck cancer patients with recent weight loss, using an omega 3 fatty acids and arginine diet could improve nutritional status and complications.
  
  
  METHODS
  A population of 30 ambulatory post surgical patients with oral and laryngeal cancer and recent weight loss was enrolled. At Hospital discharge post surgical head and neck cancer patients were asked to consume two cans per day of a specially designed omega 3 fatty acid and arginine enhanced supplement during 12 weeks.
  
  
  RESULTS
  The average age was 62.7 + 11.1 years (3 females/27 males). The average days of dietary suplementation was 90.8 + 22 days. Blood albumin, prealbumin, transferring and lymphocites concentrations improved. C reactive protein decreased. Neither weight improvement nor other anthropometric parameters improved. A positive correlation between ratio w3/w6and kg of fat mass (r = 0.69; p < 0.05) and with midarm circumference (r = 0.62; p < 0.05) were detected. Patients were divided in two groups; group I (ratio dietary intake w3/w6 < 0,51) and group II (ratio dietary intake w3/w6 > 0,51). Group II had more final fat mass than group I (17.52 + 6.3 kg vs. 13.9 + 5.1 kg; p < 0.05).
  
  
  CONCLUSIONS
  At dose taken, inmuno-enhanced formula increased blood proteins (albumin, prealbumin and transferrin) concentrations and decresed CRP. The increase of fat mass was higher in patients with better w3/w6 ratios.
authors.affiliation: Instituto de Endocrinología y Nutrición, Facultad de Medicina y Unidad de Investigación, Hospital Río Hortega, Valladolid. dadluis@yahoo.es
authors.forename: D A
authors.initials: DA
authors.lastname: de Luis
authors.forename: O
authors.initials: O
authors.lastname: Izaola
authors.forename: R
authors.initials: R
authors.lastname: Aller
authors.forename: M
authors.initials: M
authors.lastname: González-Sagrado
authors.forename: L
authors.initials: L
authors.lastname: Cuellar
authors.forename: M C
authors.initials: MC
authors.lastname: Terroba
authors.forename: T
authors.initials: T
authors.lastname: Martín
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000553:Ambulatory Care; D000704:Analysis of Variance; D001120:Arginine / Q000008:administration & dosage*; D003627:Data Interpretation, Statistical; D019587:Dietary Supplements; D002149:Energy Intake; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006258:Head and Neck Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D007830:Larynx / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000473:pathology; D009062:Mouth Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D015525:Fatty Acids, Omega-3; D001120:Arginine